Investor Alert

Dow Jones Newswires Archives | Email alerts

July 26, 2022, 5:24 p.m. EDT

Teva Pharma ADRs Jump 17% On Pending Nationwide Agreement Over Opioid Litigation

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Denny Jacob

Teva Pharmaceutical Industries Ltd. American depositary receipts jumped 17% to $8.31 in after-hours trading Tuesday after the company said it reached a nationwide agreement in principle to resolve the majority of its opioid-related litigation.

The generic drugmaker said it will pay up to $4.25 billion, including already settled cases, and about $100 million for Native American tribes, over a 13-year period. The company said the figure includes the supply of up to $1.2 billion of its generic version of Narcan over 10 years.

The agreement is pending participation by states and subdivisions, Teva said, as well as an agreement with Allergan PLC with respect to indemnification obligations and Allergan reaching a nationwide opioids settlement.

Teva said it expects that it will have documentation for the agreement, which it says will include no admission of wrongdoing, finalized within the coming weeks.

Write to Denny Jacob at denny.jacob@wsj.com

This Story has 0 Comments
Be the first to comment
More News In
Dow Jones Newswires

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.